Trastuzumab-deruxtecan before surgery for HER2-positive early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have untreated invasive HER2-positive breast cancer diagnosed by a biopsy within the last 6 weeks
- You are age 18 or older and able to sign informed consent
- Your heart pumping strength is good (left ventricular ejection fraction 50% or higher within 28 days)
- You can do usual daily activities (ECOG 0–1) and your blood and organ tests are adequate
- Your cancer is early-stage and operable (not inflammatory, not already metastatic)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
This trial tests a combination of two drugs (trastuzumab deruxtecan and an immunotherapy) given before surgery to shrink early-stage breast cancer tumors. It is for people whose tumors have low levels of HER2 and are hormone receptor positive.
This trial compares two drugs, trastuzumab rezetecan and trastuzumab deruxtecan, given before surgery to shrink HER2-positive breast cancer tumors. It aims to see which drug works better and has fewer side effects, potentially offering a more effective treatment option for patients.
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
Hear when a new HER2-positive Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.